Acomplia

Its not available yet. I think its expected to be released in the UK in
about a year and in the US sometime after that. I wonder if thats why it
supposed to be marketed under a couple of different names?

Its not really a diet pill - it works on addictions of all types - food,
drugs, alcohol, smoking,etc. Stops people from wanting whatever they are
addicted too all the time. If it works it should be revolutionary and its
for sure there will be a huge market for it.

Debra

JK@work <[email hidden]> wrote in message
news:R6Nmd.5601$b73.4868@trndny04...

Quoted message said:

Anyone know anything about this new diet pill? I just read of a 2 year

study

Quoted message said:

that showed positive results.

*50 lbs off, 6 year Atkins guy

JK Sinrod
Sinrod Stained Glass Studios
http://www.sinrodstudios.com/
Coney Island Memories
www.sinrodstudios.com/coneymemories/

"JK@work" <[email hidden]> wrote in message news:<R6Nmd.5601$b73.4868@trndny04>...

Quoted message said:

Anyone know anything about this new diet pill? I just read of a 2 year study
that showed positive results.

*50 lbs off, 6 year Atkins guy

JK Sinrod
Sinrod Stained Glass Studios
http://www.sinrodstudios.com/
Coney Island Memories
www.sinrodstudios.com/coneymemories/

http://www.technewsworld.com/story/news/38017.html

*** quote
Acomplia has also been shown to help stop smoking and increase HDL, or
"good cholesterol." The two-year study showed some side effects
depression, anxiety, irritability which did not last long. "The
results are very encouraging," said Sidney C. Smith Jr., a University
of North Carolina cardiologist who had no role in the study.
*** unquote

Sidney C. Smith, M.D., Professor Emeritus, Medicine, University of
North Carolina. Contributed to the July 2004 National Cholesterol
Education Program report funded by the National Heart, Lung and Blood
Institute which lowered the recommended cholesterol levels at which
patients should begin taking statin drugs. According to the National
Cholesterol Education Program disclosure, Smith received institutional
research support from Merck and owns stock in Medtronic and Johnson &
Johnson. (http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04_disclose.htm;
accessed 7/26/04)

*****

This study was presented to the american heart assoc., it hasn't been
published or peer reviewed!!!!

Sounds like the AHA is being complicit in garnering a lot of press for
Sanofi-Synthelabo's product

....more about Acomplia aka. Rimonabant

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=7077075&tid=nstk&sid=7077075&mid=32600

The highly anticipated obesity drug from Sanofi-Synthelabo SA SNY:
(NYSE ADR) Acomplia (Rimonabant) is a small molecule antagonist of the
CB-1 receptor. The "CB" in the receptor name stands for "cannabinoid",
and the drug blocks the same receptor whose stimulation causes the
well-known food cravings brought on by marijuana. Blockade of this
receptor not only seems to affect appetite, but also seems to help
with cravings for nicotine.

We had added SNY to our model portfolio based on promising Phase III
results that demonstrated Acomplia's efficacy against obesity and
nicotine cravings. However, recent disturbing news raising questions
about side effect of Acomplia have led us to remove our buy
recommendation for SNY.

Most worrisome is that a patient suddenly came down with multiple
sclerosis after having been a subject in a rimonabant trial. There's
some evidence that CB-1 has a neuroprotective effect under normal
conditions. So blocking its actions might conceivably expose neurons
to damage.

The MS concern comes on top of a report that Vanderbilt University
researchers are expressing concern that the diet drug Acomplia
(rimonabant) may potentially increase the risk of ectopic pregnancies
in young women, according to a report in the October issue of the
journal Nature Medicine.

Ectopic pregnancy occurs when a fertilized egg implants in tissue
outside of the uterus, and the placenta and fetus begin to develop
there. The most common site is within a fallopian tube. The Vanderbilt
researchers, in a study of the CB1 receptor which is targeted by
Acomplia, found that in pregnant mice that lacked the gene for the
receptor, or in which the receptor was blocked, the embryo failed to
go through the oviduct – the tube leading from the ovaries to the
uterus.

It is not known whether drugs that block the CB1 receptor can cause
ectopic pregnancy in humans. According to the U.S. Centers for Disease
Control and Prevention, about 100,000 ectopic pregnancies occur in the
United States each year (out of more than 6 million total pregnancies)
and account for about 9 percent of all pregnancy-related deaths in the
country.

Even though Acomplia has been tested on more than 13,000 people in
Phase III trials, if the odds are that 1 in 13,000 that it causes MS,
that would probably doom Acomplia. That there is a proposed causation
by which Acomplia's action on the nervous system leads to MS and an
actual case of MS in an Acomplia trial could preclude FDA approval.

*****

a bit about Sanofi-Synthélabo.

http://www.biopsychiatry.com/bigpharma/rimonabant.html

TC